129 related articles for article (PubMed ID: 26399130)
21. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.
Raleigh DR; Hsu IC; Braunstein S; Chang AJ; Simko JP; Roach M
Brachytherapy; 2015; 14(2):185-8. PubMed ID: 25533416
[TBL] [Abstract][Full Text] [Related]
22. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
23. [Review on the effectiveness of prostate cancer brachytherapy].
Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
[TBL] [Abstract][Full Text] [Related]
24. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
25. Importance of implant dosimetry for patients undergoing prostate brachytherapy.
Potters L; Huang D; Calugaru E; Fearn P; Lee L; Kattan MW
Urology; 2003 Dec; 62(6):1073-7. PubMed ID: 14665358
[TBL] [Abstract][Full Text] [Related]
26. [A case of primary transitional cell carcinoma of the prostate].
Morikawa H; Cho M; Takada S; Fujimoto K; Uemura H; Ozono S; Hirao Y; Natsume O
Hinyokika Kiyo; 2003 Jun; 49(6):357-60. PubMed ID: 12894737
[TBL] [Abstract][Full Text] [Related]
27. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
28. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
Stock RG; Berkowitz J; Blacksburg SR; Stone NN
BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
[TBL] [Abstract][Full Text] [Related]
29. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
30. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
31. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
32. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
33. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy.
Reed D; Wallner K; Merrick G; Buskirk S; True L
Urology; 2003 Oct; 62(4):683-8. PubMed ID: 14550443
[TBL] [Abstract][Full Text] [Related]
34. Distant and local recurrence in patients with biochemical failure after prostate brachytherapy.
Stock RG; Cesaretti JA; Unger P; Stone NN
Brachytherapy; 2008; 7(3):217-22. PubMed ID: 18635024
[TBL] [Abstract][Full Text] [Related]
35. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
[TBL] [Abstract][Full Text] [Related]
38. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M
Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
